Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Stem Cell Mobilization Capacity Is Not a Predictor of Survival in Multiple Myeloma (MM) After Autologous Stem Cell Transplantation (ASCT).

Gloria Lim, BSc, MSc, MD, Wei Xu, PhD, Trieu Young, MSc, Andrew Winter, BScN, Donna E. Reece, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Christine Chen, MD

Blood (2009) 114 (22): 2154.

https://doi.org/10.1182/blood.V114.22.2154.2154

Published: 2009

Journal Articles

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma.

Joseph R. Mikhael, MD, Sahar Zadeh, A. Keith Stewart, MD, Christine Chen, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, FRCPC, Andrew Winter, BScN, Norman Franke, Donna E. Reece, MD

Blood (2009) 114 (22): 1217.

https://doi.org/10.1182/blood.V114.22.1217.1217

Published: 2009

Journal Articles

Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients with Dialysis-Dependent Renal Failure Is Effective but Carries High Rates of Toxicity.

Lisa Chodirker, MD, Joseph R. Mikhael, M.Ed, MD, Keith Stewart, MD, Andrew Winter, BScN, Donna E. Reece, MD, Norman Franke, MD, Suzanne Trudel, MD, Vishal Kukreti, M.Sc, MD, Wei Xu, PhD, Christine I. Chen, M.Ed, MD

Blood (2007) 110 (11): 954.

https://doi.org/10.1182/blood.V110.11.954.954

Published: 2007

Journal Articles

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma: Improved Outcomes in Patients with Longer Disease Free Interval after First ASCT.

Joseph R. Mikhael, MD, Sahar Zadeh, BSc, Sara Samiee, MD, Keith Stewart, MD, Christine Chen, MD, Suzanne Trudel, MD, Vishal Kukreti, MD, Norman Franke, MD, Andrew Winter, BScN, Drew Phillips, Donna Reece, MD

Blood (2007) 110 (11): 946.

https://doi.org/10.1182/blood.V110.11.946.946

Published: 2007

Journal Articles

Outcome after Second Autologous Stem Cell Transplantation as Salvage Therapy in Patients with Relapsed Multiple Myeloma.

Joseph R. Mikhael, MD, Sara Samiee, MD, A. Keith Stewart, MD, Christine Chen, MD, Suzanne Trudel, MD, Norman Franke, MD, Andrew Winter, BScN, Hong Chang, MD, PhD, Donna E. Reece, MD

Blood (2004) 104 (11): 943.

https://doi.org/10.1182/blood.V104.11.943.943

Published: 2004

NARROW

Stem Cell Mobilization Capacity Is Not a Predictor of Survival in Multiple Myeloma (MM) After Autologous Stem Cell Transplantation (ASCT).

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma.

Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients with Dialysis-Dependent Renal Failure Is Effective but Carries High Rates of Toxicity.

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma: Improved Outcomes in Patients with Longer Disease Free Interval after First ASCT.

Outcome after Second Autologous Stem Cell Transplantation as Salvage Therapy in Patients with Relapsed Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Stem Cell Mobilization Capacity Is Not a Predictor of Survival in Multiple Myeloma (MM) After Autologous Stem Cell Transplantation (ASCT).

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma.

Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients with Dialysis-Dependent Renal Failure Is Effective but Carries High Rates of Toxicity.

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma: Improved Outcomes in Patients with Longer Disease Free Interval after First ASCT.

Outcome after Second Autologous Stem Cell Transplantation as Salvage Therapy in Patients with Relapsed Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only